<DOC>
	<DOCNO>NCT00511082</DOCNO>
	<brief_summary>- To investigate safety tolerability OPB-31121 follow repeat oral administration OPB-31121 patient Non-Hodgkin 's Lymphoma ( NHL ) Multiple Myeloma ( MM ) - To determine potential dose-limiting toxicity maximum-tolerated dose patient treat OPB-31121 - To determine pharmacokinetics anti-tumor efficacy OPB-31121 patient</brief_summary>
	<brief_title>Phase 1 Study OPB-31121 Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>The study design single-center , open-label , phase 1 dose-escalation study ass safety , tolerability , pharmacokinetics , anti-tumor efficacy OPB-31121 patient relapse refractory NHL MM . - To investigate safety tolerability OPB-31121 follow repeat oral administration OPB-31121 patient NHL MM - To determine potential dose-limiting toxicity maximum-tolerated dose patient treat OPB-31121 - To determine pharmacokinetics anti-tumor efficacy OPB-31121 patient</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Patients must relapse refractory NHL histologically confirm . Relapsed refractory NHL MM patient must experience treatment failure . Chinese patient age 18 year old time give informed consent . Performance status score 02 accord incriteria Eastern Cooperative Oncology Group ( ECOG ) Life expectancy longer 3 month . Patients must adequate vital organ function . Patients willing comply visit schedule hospitalization outpatient clinic . Patients prior chemotherapy , immunotherapy , cytokine therapy , major surgery , radiotherapy index lesion must complete minimum period 4 week recover related toxicity ( NCI CTCAE grade 0 1 ) registration . Patients systemic corticosteroid therapy ( &gt; 10 mg prednisone equivalent ) must complete minimum 1 week recover related toxicity ( NCI CTCAE grade 0 1 ) registration . Patients prior stem cell transplantation must least 8 week recover related toxicity ( NCI CTCAE grade 0 1 ) registration . Patients receive another investigational agent receive another investigational agent within 6 month . Patients receive concurrent chemotherapy , biologic agent , radiotherapy . Patients receive concurrent administration warfarin . NHL MM patient candidate autologous stem cell transplantation exclude study . Patients primary malignancy except squamous basal cell skin cancer cervical cancer situ . Patients acute lymphoblastic lymphoma/leukaemia , POEMS syndrome plasma cell leukaemia . Lymphoma patient symptomatic CNS involvement . Patients uncontrolled intercurrent illness . Known HIVpositive/AIDS patient . Female patient pregnant , lactate , possibly pregnant , wish become pregnant study period . Patients unable use appropriate contraceptive method study period least 6 month completion study Patients need receive follow treatment therapeutic agent study period : Anticancer drug study drug Systemic corticosteroid therapy ( &gt; 10 mg prednisone equivalent ) Radiotherapy primary therapy Immunotherapy Surgical therapy CYP3A4 CYP2C9 enzyme inducer inhibitor , substrate , CYP2B6 , CYP2C8 , CYP2D6 substrates .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>